Verastem (NASDAQ:VSTM) Shares Gap Up – Should You Buy?

Shares of Verastem, Inc. (NASDAQ:VSTM) gapped up before the market opened on Wednesday. The stock had previously closed at $7.45, but opened at $8.00. Verastem shares last traded at $8.7640, with a volume of 10,572,543 shares traded.

Key Stories Impacting Verastem

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: VS-7375 showed meaningful anti-tumor activity across KRAS G12D-mutated pancreatic, lung and colorectal cancers. In second-line pancreatic ductal adenocarcinoma, the drug produced a 50% confirmed objective response rate, including two complete responses in second-line-or-later disease. The results support Verastem’s plans to advance the program into Phase III testing. VS-7375 clinical data
• Positive Sentiment: BTIG Research raised its price target from $18 to $24 and initiated or reaffirmed a Buy rating. The new target implies substantial upside from the recent trading level, adding analyst support to the clinical-data-driven rally.
• Positive Sentiment: Verastem priced a roughly $250 million financing, providing capital to support late-stage development of VS-7375 and other oncology programs. The additional cash reduces near-term funding risk as the company prepares for Phase III. Verastem financing announcement
• Neutral Sentiment: Michael P. Bailey will become president and CEO on January 1, 2027, succeeding retiring CEO Daniel Paterson. The planned transition provides leadership continuity, but investors will monitor execution as the company moves toward pivotal trials. CEO succession announcement
• Negative Sentiment: The financing involves approximately 30.9 million new common shares plus pre-funded warrants priced at $8 per share, creating substantial dilution for existing shareholders. In addition, VS-7375 remains investigational, and the company faces clinical, regulatory and competitive risks as it advances toward Phase III.

Wall Street Analyst Weigh In

A number of analysts have weighed in on VSTM shares. Royal Bank Of Canada restated an “outperform” rating and issued a $19.00 price target (up from $14.00) on shares of Verastem in a research note on Thursday. Wall Street Zen raised Verastem from a “sell” rating to a “hold” rating in a research report on Sunday, September 27th. Weiss Ratings raised Verastem from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 4th. Guggenheim set a $12.00 price objective on Verastem and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Wolfe Research began coverage on Verastem in a report on Thursday, September 17th. They issued an “outperform” rating on the stock. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.50.

Verastem Stock Up 19.7%

The firm has a market cap of $835.90 million, a PE ratio of -3.47 and a beta of 0.39. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25. The firm’s 50-day moving average price is $7.61 and its two-hundred day moving average price is $5.94.

Verastem (NASDAQ:VSTM) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.08. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. The business had revenue of $40.08 million during the quarter, compared to analysts’ expectations of $22.88 million. As a group, equities research analysts expect that Verastem, Inc. will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Dan Paterson sold 44,121 shares of Verastem stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $8.00, for a total transaction of $352,968.00. Following the sale, the chief executive officer directly owned 652,712 shares in the company, valued at $5,221,696. This trade represents a 6.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 48,044 shares of company stock worth $381,484. 1.94% of the stock is owned by company insiders.

Hedge Funds Weigh In On Verastem

Large investors have recently bought and sold shares of the stock. Opaleye Management Inc. acquired a new stake in shares of Verastem during the second quarter worth about $6,876,000. Bank of New York Mellon Corp acquired a new stake in shares of Verastem in the 2nd quarter valued at about $706,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Verastem by 157.2% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 569,195 shares of the biopharmaceutical company’s stock valued at $2,174,000 after purchasing an additional 347,872 shares during the period. Seven Fleet Capital Management LP grew its stake in Verastem by 715.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 123,400 shares of the biopharmaceutical company’s stock worth $654,000 after buying an additional 108,260 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Verastem by 31.6% during the 1st quarter. Bank of America Corp DE now owns 416,985 shares of the biopharmaceutical company’s stock worth $2,210,000 after buying an additional 100,123 shares during the last quarter. Institutional investors and hedge funds own 88.37% of the company’s stock.

Verastem Company Profile

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.